Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis (Q80203516)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17453363%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17453363%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

29 December 2019

main subject

1 reference

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17453363%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

J Norum

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17453363%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

J A Olsen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17453363%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

E A Wist

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17453363%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17453363%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17453363%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17453363%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

153-164

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17453363%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17453363%20AND%20SRC:MED&resulttype=core&format=json

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report

29 December 2019

cites work

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Quality of life among long-term breast cancer survivors: a systematic review

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Health economic guidelines--similarities, differences and some implications

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer?

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Adjuvant trastuzumab for breast cancer

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Herceptin and early breast cancer: a moment for caution

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

First-line Herceptin monotherapy in metastatic breast cancer

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Patient demand and politics push Herceptin forward

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Discounting health outcomes in economic evaluation: the ongoing debate

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Adjuvant trastuzumab for breast cancer: editorial does not mention health economics of drug

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Emerging standardization in pharmacoeconomics

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Combination of Trastuzumab and Vinorelbine in Metastatic Breast Cancer

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Weekly schedule of vinorelbine in pretreated breast cancer patients

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Lumpectomy or mastectomy? Is breast conserving surgery too expensive?

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1080/02841860601096841

Identifiers

DOI

10.1080/02841860601096841

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17453363%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference